Sildenafil Teva
From £3.99
Research Studies on Sildenafil Effectiveness
Pivotal Clinical Trials and Efficacy Data
Sildenafil's journey from laboratory to pharmacy shelf is supported by robust clinical evidence spanning over two decades. The initial pivotal trials involved more than 3,000 men across multiple countries, demonstrating significant improvements in erectile function compared to placebo. These foundational studies showed success rates ranging from 70-85% depending on the underlying cause of erectile dysfunction.
Cardiovascular Safety Research
Given sildenafil's mechanism of action affecting blood vessels, extensive cardiovascular safety studies have been conducted. The landmark studies examined men with various heart conditions, including those with stable coronary artery disease. Research published in major cardiology journals confirmed that sildenafil can be safely used in most men with cardiovascular disease, provided they're not taking nitrate medications.
Real-World Evidence and Long-Term Studies
Beyond controlled clinical trials, real-world evidence from millions of prescriptions has reinforced sildenafil's safety profile. Long-term studies following patients for several years have shown sustained effectiveness without significant tolerance development. These studies also confirmed that both branded Viagra and generic sildenafil formulations demonstrate equivalent bioavailability and clinical outcomes.
Comparative Effectiveness Research
Head-to-head studies comparing sildenafil with other PDE5 inhibitors have shown similar overall efficacy rates, with individual patient response varying based on personal factors. Research indicates that approximately 70% of men who don't respond to one PDE5 inhibitor may respond to another, highlighting the importance of personalised treatment approaches.
Quality of Life and Psychological Impact Studies
Clinical research extends beyond physical effectiveness to examine psychological and relationship benefits. Studies using validated questionnaires demonstrate significant improvements in confidence, relationship satisfaction, and overall quality of life. Partners of men using sildenafil also reported improved relationship satisfaction in several studies.
Safety Monitoring and Post-Market Surveillance
Ongoing post-market surveillance continues to monitor sildenafil's safety profile across diverse populations. Regulatory agencies worldwide maintain databases tracking adverse events, confirming the medication's favourable risk-benefit ratio when used appropriately. This continuous monitoring has led to refined prescribing guidelines and enhanced patient safety protocols.
Dosing Optimisation Research
Studies examining optimal dosing strategies have established that starting with 50mg provides the best balance of effectiveness and tolerability for most men. Research supports dose adjustment to 25mg for those experiencing side effects or 100mg for insufficient response. Clinical data confirms that taking sildenafil on an empty stomach optimises absorption and onset time.
